Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olutasidenib + HMA in IDH1-mutated Higher-risk MDS, CMML, or Advanced MPN
NCT06597734Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2025
- Primary completion
- Jun 2026
01
Overview
Phase 2, open-label, single-arm trial of olutasidenib in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) and Myeloproliferative Neoplasm (MPN), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Overall Response Rate. Planned start Jan 2025; status: withdrawn.
02
Drugs
olutasidenib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)Myeloproliferative Neoplasm (MPN)
Beyond the preview
Go deeper on NCT06597734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597734.